Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

Overexpression of programmed death‐1 (PD‐1) ligands contributes to an immunosuppressive microenvironment. Nivolumab is a PD‐1‐blocking antibody that inhibits the PD‐1 pathway and showed good efficacy in several types of malignancy. This phase II study examined the efficacy and safety of nivolumab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Dai, Hatake, Kiyohiko, Kinoshita, Tomohiro, Fukuhara, Noriko, Choi, Ilseung, Taniwaki, Masafumi, Ando, Kiyoshi, Terui, Yasuhito, Higuchi, Yusuke, Onishi, Yasushi, Abe, Yasunobu, Kobayashi, Tsutomu, Shirasugi, Yukari, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448600/
https://www.ncbi.nlm.nih.gov/pubmed/28267244
http://dx.doi.org/10.1111/cas.13230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448600/
https://www.ncbi.nlm.nih.gov/pubmed/28267244
http://dx.doi.org/10.1111/cas.13230

Ejemplares similares